GlaxoSmithKline Pharmaceuticals Limited Earnings Summary — Q1 FY2027
GlaxoSmithKline Pharmaceuticals Reports 16.5% Revenue Growth and Robust Profit Expansion in Q1 FY2027
Quarterly Business Intelligence
AI Quarterly Scorecard™
Computed deterministically from the last 10 reported quarters.
Quarterly Business Momentum
- Revenue declined 5.7% sequentially in Q1 FY2027.
- Revenue of ₹938 Cr is 16.6% higher year-on-year.
- Revenue has compounded at 0.4% annualised over the last 10 quarters.
- Net profit of ₹237 Cr is 15.7% above the same quarter last year.
- Profit growth is trailing revenue growth this quarter.
- Net profit has compounded at 9.2% annualised across the period.
- Operating margin stands at 31.5% in Q1 FY2027.
- Operating margin expanded by 29 bps year-on-year.
- Over the last two years operating margin has expanded by 319 bps.
- PBT margin is 34.4%.
- Expense growth of 16.1% remained below revenue growth of 16.6%.
- Operating profit of ₹296 Cr is 17.6% higher year-on-year.
- Operating leverage has been under pressure recently.
- 4 of the last 6 measured quarters delivered year-on-year revenue growth.
- Overall quarterly business momentum scores 63/100 (Healthy) on the latest 10 quarters.
- Business momentum remains positive heading into the next quarter.
Quarterly Financials
Last 10 Reported Quarters • All figures in ₹ Crore • Margins in %
| Metric | Trend | Latest Q1 FY2027 | Q4 FY2026 | Q3 FY2026 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q4 FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | Stable | 938 | 995 | 1,041 | 980 | 805 | 974 | 949 | 1,011 | 815 | 930 |
| Expenses | Stable | 643 | 644 | 670 | 644 | 554 | 641 | 658 | 689 | 584 | 673 |
| Operating Profit | Improving | 296 | 351 | 371 | 336 | 251 | 333 | 292 | 322 | 231 | 257 |
| Operating Margin | Stable | 31.5% | 35.3% | 35.7% | 34.3% | 31.2% | 34.2% | 30.8% | 31.8% | 28.3% | 27.7% |
| Other Income | Improving | 44 | 36 | 50 | 36 | 44 | 41 | 35 | 39 | 36 | 32 |
| Interest | Volatile | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 |
| Depreciation | Stable | 16 | 13 | 20 | 17 | 16 | 15 | 19 | 17 | 16 | 18 |
| Profit Before Tax | Improving | 322 | 373 | 400 | 354 | 279 | 359 | 308 | 344 | 249 | 271 |
| Tax | Improving | 85 | 95 | 104 | 97 | 74 | 96 | 78 | 91 | 67 | 76 |
| Net Profit | Improving | 237 | 278 | 296 | 257 | 205 | 263 | 230 | 253 | 182 | 194 |
| Net Margin | Stable | 25.3% | 27.9% | 28.4% | 26.3% | 25.5% | 27.0% | 24.2% | 25.0% | 22.4% | 20.9% |
Key Takeaways
- Revenue from operations grew 16.5% year-on-year to ₹938.44 crore, reflecting steady demand in the core pharmaceutical segment.
- Consolidated Net Profit rose to ₹237.18 crore, a 15.7% increase compared to the same quarter last year, despite a sequential dip from Q4 FY26.
- Purchase of stock-in-trade increased significantly to ₹378.62 crore from ₹232.06 crore YoY, indicating shifting procurement or inventory strategies.
- The board approved a two-year re-appointment for Mr. Bhushan Akshikar as Managing Director, ensuring leadership continuity through 2028.
- Board composition changes occurred with the resignation of Mr. Subesh Williams and the appointment of Ms. Karine J F Natland, SVP Asia Pacific at GSK.
- The company maintains a high-quality balance sheet with no long-term borrowings and only one reportable segment: Pharmaceuticals.
Management Guidance
Management is focused on reaching over 1 billion patients this decade and doubling sales of General Medicines' growth engines by 2030 globally, with a localized strategy led by the newly appointed regional leadership.
Sentiment Shift
Stable
Year-on-year growth remains strong across both top and bottom lines, though sequential performance normalized following a strong year-end FY26.
Outlook
The outlook remains positive as the company continues to pivot toward specialty medicines and vaccines while leveraging its asset-light model and exceptional capital efficiency (61% ROCE).
From the Annual Report (Key Quotes)
“Karine J F Natland has led with the vision of transforming the business... doubling the sales of General Medicines' growth engines by 2030.”
“Final dividend of Rs. 57 per equity share for the year ended 31st March 2026 had been approved by the shareholders.”
“The Group has only one reportable segment which is Pharmaceuticals.”
Official Quarterly Documents
Ask AI about this quarter
This summary is AI-generated from GlaxoSmithKline Pharmaceuticals Limited's latest quarterly filing and earnings call. For informational purposes only — not investment advice.
← Back to GlaxoSmithKline Pharmaceuticals Limited AI analysis